• 1
    Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ 2006 Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 65: 8792.
  • 2
    Richards J, Leslie W, Joseph L, Siminoski K, Hanley D, Adachi J, Brown J, Morin S, Papaioannou A, Josse R, Prior J, Davison K, Tenenhouse A, Goltzman D; for the CaMos Study Group 2007 Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res. 22: 228234.
  • 3
    Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, Hanley DA, Olszynski WP, Murray TM, Anastassiades T, Hopman W, Brown JP, Kirkland S, Joyce C, Papaioannou A, Poliquin S, Tenenhouse A, Papadimitropoulos EA 2003 The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 14: 895904.
  • 4
    Raisz LG 2005 Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115: 33183325.
  • 5
    Goltzman D 2002 Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 1: 784796.
  • 6
    Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME 2006 Playing with bone and fat. J Cell Biochem 98: 251266.
  • 7
    Gimble JM, Nuttall ME 2004 Bone and fat: Old questions, new insights. Endocrine 23: 183188.
  • 8
    Chan GK, Duque G 2002 Age-related bone loss: Old bone, new facts. Gerontology 48: 6271.
  • 9
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ 2006 Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 54: 782789.
  • 10
    Nuttall ME, Gimble JM 2004 Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4: 290294.
  • 11
    Nuttall ME, Gimble JM 2000 Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 27: 177184.
  • 12
    Sambrook P, Cooper C 2006 Osteoporosis. Lancet 367: 20102018.
  • 13
    Melo M, Qiu F, Sykora K, Juurlink D, Laupacis A, Mamdani M 2006 Persistence with bisphosphonate therapy in older people. J Am Geriatr Soc 54: 10151016.
  • 14
    Still K, Phipps RJ, Scutt A 2003 Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. Calcif Tissue Int 72: 143150.
  • 15
    Itoh F, Aoyagi S, Furihata-Komatsu H, Aoki M, Kusama H, Kojima M, Kogo H 2003 Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 477: 916.
  • 16
    Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR 1999 Multilineage potential of adult human mesenchymal stem cells. Science 284: 143147.
  • 17
    David V, Martin A, Lafage-Proust MH, Malaval L, Peyroche S, Jones DB, Vico L, Guignandon A 2007 Mechanical loading down-regulates peroxisome proliferator-activated receptor gamma in bone marrow stromal cells and favors osteoblastogenesis at the expense of adipogenesis. Endocrinology 148: 25532562.
  • 18
    Duque G, El Abdaimi K, Macoritto M, Miller MM, Kremer R 2002 Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: Changes with aging and hormone deprivation. Biochem Biophys Res Commun 299: 446454.
  • 19
    Duque G 2003 Will reducing adipogenesis in bone increase bone mass?: PPARgamma2 as a key target in the treatment of age-related bone loss. Drug News Perspect 16: 341346.
  • 20
    Prestwood KM, Raisz LG 2002 Prevention and treatment of osteoporosis. Clin Cornerstone 4: 3141.
  • 21
    Khan AW, Khan A 2006 Anabolic agents: A new chapter in the management of osteoporosis. J Obstet Gynaecol Can 28: 136141.
  • 22
    Partridge NC, Li X, Qin L 2006 Understanding parathyroid hormone action. Ann N Y Acad Sci 1068: 187193.
  • 23
    Duque G, Macoritto M, Dion N, Ste-Marie LG, Kremer R 2003 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab 288: E723E730.
  • 24
    Kendler DL 2006 Strontium ranelate-data on vertebral and nonvertebral fracture efficacy and safety: Mechanism of action. Curr Osteoporos Rep 4: 3439.
  • 25
    Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 12261235.
  • 26
    Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S, Nuttall ME 2006 Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 39: 13611372.
  • 27
    Kong J, Li YC 2006 Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab 290: E916E924.
  • 28
    Duque G, Macoritto M, Kremer R 2004 Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology 5: 421429.
  • 29
    Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, Tomiyama H, Sakamoto Y, Matsumoto T 2002 Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 143: 23492356.
  • 30
    Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T 2005 Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280: 73177325.
  • 31
    Russell RG 2006 Bisphosphonates: From bench to bedside. Ann N Y Acad Sci 1068: 367401.
  • 32
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 14751480.
  • 33
    Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 25772586.
  • 34
    Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N 1996 Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18: 914.
  • 35
    Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G 1998 Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22: 455461.
  • 36
    Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS 2004 Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25: 41054115.
  • 37
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T 1999 Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 13631374.
  • 38
    Rodan GA, Reszka AA 2002 Bisphosphonate mechanism of action. Curr Mol Med 2: 571577.
  • 39
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687694.
  • 40
    Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, Carbonell J, Mellibovsky L, Nogues X, Ballester J, Aubia J 1998 Effect of alendronate on cultured normal human osteoblasts. Bone 22: 233239.